Phase II study of dose-modified busulfan by real-time targeting in allogeneic transplantation for myeloid malignancy
Cancer Science, 06/08/2012
Clinical Article
Kuwatsuka Y et al. – The findings suggest that individual dose adjustment based on busulfan (BU)–pharmacokinetics was feasible and effective in the current phase II study.



